Recombinant Human Glypican 1/GPC1 Protein, Active
Beta LifeScience
SKU/CAT #: BLK-02048P-100UG
Human Glypican 1 on Tris-Bis PAGE under reduced condition. The purity is greater than 95%.
Recombinant Human Glypican 1/GPC1 Protein, Active
Beta LifeScience
SKU/CAT #: BLK-02048P-100UG
Collections: Other recombinant proteins, Recombinant proteins
Our products are highly customizable to meet your specific needs. You can choose options such as endotoxin removal, liquid or lyophilized forms, preferred tags, and the desired functional sequence range for proteins. Submitting a written inquiry expedites the quoting process.
Product Overview
Description | Recombinant Human Glypican 1/GPC1 Protein is expressed from HEK293 with His tag at the C-Terminus.It contains Asp24-Ser530. |
Purity | > 95% as determined by Tris-Bis PAGE;> 95% as determined by HPLC |
Accession | P35052 |
Target Symbol | Glypican 1/GPC1 |
Synonyms | Glypican-1; FLJ38078; GPC1 |
Species | Human |
Expression System | HEK293 |
Tag | C-His |
Expression Range | Asp24-Ser530 |
Mol. Weight | The protein has a predicted MW of 57.1 kDa. Due to glycosylation, the protein migrates to 70-135 kDa based on Tris-Bis PAGE result. |
Form | Lyophilized |
Formulation | Lyophilized from 0.22um filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization. |
Endotoxin | Less than 1EU per ug by the LAL method. |
Activity | Immobilized Human FGF basic at 0.5ug/ml (100ul/Well) on the plate. Dose response curve for Human Glypican 1, His Tag with the EC50 of 12.6ng/ml determined by ELISA. Contact us for detailed testing images. |
Storage | Reconstituted protein stable at -80°C for 12 months, 4°C for 1 week. Use a manual defrost freezer and avoid repeated freeze-thaw cycles. |
Shipping | Shipped at ambient temperature. |
Gene Background | CAR-T cells targeting glypican-1 (GPC1)-specific human and murine CAR-T cells generated from our original anti-human/mouse GPC1 antibody showed strong antitumor effects in xenogeneic and syngeneic mouse models, respectively. Importantly, the murine CAR-T cells enhanced endogenous T cell responses against a non-GPC1 tumor antigen through the mechanism of antigen-spreading and showed synergistic antitumor effects with anti-PD-1 antibody without any adverse effects in syngeneic models. |